Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €16.89 EUR
Change Today -0.18 / -1.05%
Volume 25.6K
ALM On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
Continuous
As of 7:05 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

almirall sa (ALM) Snapshot

Open
€17.11
Previous Close
€17.07
Day High
€17.25
Day Low
€16.79
52 Week High
07/22/15 - €19.36
52 Week Low
09/25/14 - €10.75
Market Cap
2.9B
Average Volume 10 Days
276.3K
EPS TTM
€2.82
Shares Outstanding
173.0M
EX-Date
06/1/15
P/E TM
6.0x
Dividend
€0.20
Dividend Yield
1.18%
Current Stock Chart for ALMIRALL SA (ALM)

Related News

No related news articles were found.

almirall sa (ALM) Related Businessweek News

No Related Businessweek News Found

almirall sa (ALM) Details

Almirall, S.A., a pharmaceutical company, researches, develops, manufactures, and markets proprietary and licensed medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections; and gastrointestinal diseases, such as irritable bowel syndrome, as well as for pain. Its products include LAS100977, a potent bronchodilator, which is in phase IIa clinical trial for the treatment of asthma and chronic obstructive pulmonary disease (COPD); LAS190792, a dual long-acting muscarinic antagonist ß2 agonist that is in Phase I clinical for treating COPD; and LAS40464, an aclidinium bromide and formoterol for the treatment of COPD. The company also develops LAS41004, a compound that is in Phase II clinical trials for the treatment of psoriasis and/or atopic dermatitis; LAS41008, which is in Phase III clinical trial for treating psoriasis; and Sativex, an oromucosal spray is in Phase III clinical trial for the treatment of spasticity in patients with multiple sclerosis. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

1,993 Employees
Last Reported Date: 02/23/15
Founded in 1943

almirall sa (ALM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

almirall sa (ALM) Key Developments

Almirall Reports Earnings Results for the First Half on 2015; Provides Revenue Guidance for the Year 2015

Almirall reported earnings results for the first half on 2015. For the period, the company's total revenues were EUR 407.9 million, which represents a drop of 5.9% compared to last year's first half result of EUR 433.4 million. Total revenues comprised net sales of EUR 359.4 million Gross profit was EUR 248.3 million, which represents 69.1% of net sales. Gross operating profit (EBITDA) of EUR 123.4 million, compared with EUR 61.4 million in the first half of last year. The company's net income and normalized net income were EUR 58.8 million and EUR 63.8 million, a significant increase in comparison to last year. The company maintained the guidance for 2015 and expects total revenues in the range of EUR 720 million to EUR 750 million and net sales between EUR 650 million to EUR 680 million.

Almirall, S.A., H1 2015 Earnings Call, Jul 28, 2015

Almirall, S.A., H1 2015 Earnings Call, Jul 28, 2015

Laboratorios Almirall S.A. Wins GBP 230 Million Multiple Awardees Contract for Supplying Generic Pharmaceuticals

Laboratorios Almirall S.A. announced that it won a Wins GBP 230 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic pharmaceuticals. Dates detailed below with options to extend up to a maximum of 48 months. Potential periods of call-offs under the framework agreement: 100 % oral products: All regions July 7, 2015 to February 28, 2017 (20 months), 33% hospital only products: DLN/DNW July 7, 2015 to June 30, 2017 (24 months), Housekeeping products: DLS/DNE July 1, 2015 to February 29, 2016 (8 months) and DCE/DSW July 1, 2015 to October 31, 2016 (16 months).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALM:SM €16.89 EUR -0.18

ALM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $11.00 USD 0.00
Nektar Therapeutics $10.75 USD -0.30
Santen Pharmaceutical Co Ltd ¥1,818 JPY +14.00
Sucampo Pharmaceuticals Inc $25.29 USD -1.57
Synergy Health PLC 1,619 GBp +30.00
View Industry Companies
 

Industry Analysis

ALM

Industry Average

Valuation ALM Industry Range
Price/Earnings 6.2x
Price/Sales 3.8x
Price/Book 2.2x
Price/Cash Flow 5.4x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALMIRALL SA, please visit www.almirall.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.